Veradigm (MDRX) Competitors

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Do analysts rate MDRX or OMCL?

Veradigm currently has a consensus target price of $13.00, suggesting a potential upside of 157.43%. Omnicell has a consensus target price of $44.83, suggesting a potential upside of 56.27%. Given Veradigm's higher possible upside, equities analysts plainly believe Veradigm is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Is MDRX or OMCL more profitable?

Omnicell has a net margin of 1.87% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.60% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	1.87%	4.60%	2.56%

Does the media refer more to MDRX or OMCL?

In the previous week, Veradigm had 1 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for Veradigm and 3 mentions for Omnicell. Omnicell's average media sentiment score of 0.63 beat Veradigm's score of 0.32 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradigm	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation & earnings, MDRX or OMCL?

Omnicell has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.36	N/A	N/A	N/A
Omnicell	$1.11B	1.21	$12.53M	$0.46	62.37

Do institutionals & insiders hold more shares of MDRX or OMCL?

97.7% of Omnicell shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 2.5% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, MDRX or OMCL?

Veradigm has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Omnicell beats Veradigm on 9 of the 13 factors compared between the two stocks.